Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 9/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710651 | 1.00 | HCRTR2 (0.35) | HCRTR2 | |
| SCHEMBL24375001 | 0.88 | ATM (0.33) | HCRTR2 | |
| SCHEMBL18513346 | 0.88 | ATM (0.33) | HCRTR2 | |
| SCHEMBL22022410 | 0.87 | CHRNB2 (0.31) | — | |
| SCHEMBL23136552 | 0.86 | HCRTR2 (0.32) | HCRTR2 | |
| SCHEMBL22996017 | 0.85 | MMP2 (0.33) | HCRTR2 | |
| SCHEMBL25492845 | 0.85 | MMP2 (0.33) | HCRTR2 | |
| SCHEMBL24098413 | 0.84 | HCRTR2 (0.31) | HCRTR2 | |
| SCHEMBL20643466 | 0.84 | PDK1 (0.32) | HCRTR2 | |
| SCHEMBL22372628 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10875884-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2019-05-09 | — | — | US | disclosed |
| US-20190127737-A1 | SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III | IONIS PHARMACEUTICALS, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190016748-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9957292-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9943604-B2 | Targeted therapeutic nucleosides and their use | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | HCRTR2 320/4885 |
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, LDLR | HCRTR2 3050/4885 |
| US-10875884-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | TEK, PLIN3, FABP3 | HCRTR2 3870/4885 |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | HCRTR2 3728/4885 |
| US-20190016748-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | HCRTR2 3870/4885 |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | HCRTR2 4735/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | HCRTR2 4257/4885 |
| US-20190127737-A1 | SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III | APOB, APOL1, RBM3 | HCRTR2 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.